Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00002166
- Locations
- 🇺🇸
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT00000649
- Locations
- 🇺🇸
Univ of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Cooper Green Hosp, Birmingham, Alabama, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2000
- Registration Number
- NCT00002368
- Locations
- 🇺🇸
Dr G Michael Wool, Los Angeles, California, United States
🇺🇸Northwestern Univ / Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸Rush Presbyterian / Saint Luke's Med Ctr / Infect Dis, Chicago, Illinois, United States
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT00002323
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT00002381
- Locations
- 🇺🇸
Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States
🇺🇸Roger Williams Med Ctr, Providence, Rhode Island, United States
A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT00002407
- Locations
- 🇺🇸
Cornell AIDS Clinical Trials Unit, New York, New York, United States
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Parexel
- Target Recruit Count
- 225
- Registration Number
- NCT00002347
- Locations
- 🇺🇸
PAREXEL Intl Corp / InterCo Collaboration Ctr, Waltham, Massachusetts, United States
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Abbott
- Registration Number
- NCT00004580
- Locations
- 🇺🇸
Univ of Cincinnati Med Ctr / Holmes Div Mail Loc 0405, Cincinnati, Ohio, United States
🇺🇸Pacific Oaks Research, Beverly Hills, California, United States
🇺🇸Duke Univ Med Ctr / Infectious Disease Clinic, Durham, North Carolina, United States
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 300
- Registration Number
- NCT00004581
- Locations
- 🇨🇦
Clinique Medicale L'Actuele, Montreal, Quebec, Canada
🇨🇦Montreal Chest Institute, Montreal, Quebec, Canada
🇺🇸Tower ID Med Associates, Los Angeles, California, United States
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00002324
- Locations
- 🇺🇸
UCSD Treatment Ctr, San Diego, California, United States
🇺🇸Saint Francis Mem Hosp, San Francisco, California, United States
🇺🇸Univ of Utah School of Medicine, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.